About Verax Biomedical
Verax Biomedical is a company based in Marlborough (United States) founded in 1999.. Verax Biomedical has raised $72.3 million across 12 funding rounds from investors including BioVentures MedTech Funds, Teknoinvest and KB Partners. The company has 23 employees as of December 31, 2022. Verax Biomedical offers products and services including Platelet PGD Test, Platelet PGD prime, Red Cell PGD Test, and Cell Therapy PGD Test. Verax Biomedical operates in a competitive market with competitors including OpGen, Avails Medical, Resistell, NOWDiagnostics and HandyLab, among others.
- Headquarter Marlborough, United States
- Employees 23 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$498.01 K (USD)49as on Dec 31, 2023
-
Net Profit
$-10.76 K (USD)-207as on Dec 31, 2023
-
EBITDA
-
Total Equity Funding
$72.3 M (USD)
in 12 rounds
-
Latest Funding Round
$2.54 M (USD), Series D
Sep 18, 2019
-
Investors
BioVentures MedTech Funds
& 5 more
-
Employee Count
23
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Verax Biomedical
Verax Biomedical offers a comprehensive portfolio of products and services, including Platelet PGD Test, Platelet PGD prime, Red Cell PGD Test, and Cell Therapy PGD Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Rapid test for detecting bacterial contamination in platelets
Enhanced test for Acinetobacter detection in platelets
Test for bacterial detection in red blood cells
Test for bacterial contamination in cell therapy products
Unlock access to complete
Unlock access to complete
Funding Insights of Verax Biomedical
Verax Biomedical has successfully raised a total of $72.3M across 12 strategic funding rounds. The most recent funding activity was a Series D round of $2.54 million completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Series D — $2.5M
-
First Round
First Round
(01 Jul 2003)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2019 | Amount | Series D - Verax Biomedical | Valuation |
investors |
|
| Nov, 2017 | Amount | Series D - Verax Biomedical | Valuation |
investors |
|
| Jun, 2016 | Amount | Series D - Verax Biomedical | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Verax Biomedical
Verax Biomedical has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include BioVentures MedTech Funds, Teknoinvest and KB Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in emerging and growth-stage MedTech companies is facilitated.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Tech & Life Sciences focused VC firm investing in early stage startups in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Verax Biomedical
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Verax Biomedical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Verax Biomedical Comparisons
Competitors of Verax Biomedical
Verax Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, Avails Medical, Resistell, NOWDiagnostics and HandyLab, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| domain | founded_year | HQ Location |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| domain | founded_year | HQ Location |
Antibiotic susceptibility testing is provided via bacterial movement detection.
|
|
| domain | founded_year | HQ Location |
Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic assays and automation platforms are developed.
|
|
| domain | founded_year | HQ Location |
Instruments and assays for molecular pathogen detection are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Verax Biomedical
Frequently Asked Questions about Verax Biomedical
When was Verax Biomedical founded?
Verax Biomedical was founded in 1999 and raised its 1st funding round 4 years after it was founded.
Where is Verax Biomedical located?
Verax Biomedical is headquartered in Marlborough, United States. It is registered at Marlborough, Massachusetts, United States.
Is Verax Biomedical a funded company?
Verax Biomedical is a funded company, having raised a total of $72.3M across 12 funding rounds to date. The company's 1st funding round was a Series D of $12.61M, raised on Jul 01, 2003.
How many employees does Verax Biomedical have?
As of Dec 31, 2022, the latest employee count at Verax Biomedical is 23.
What is the annual revenue of Verax Biomedical?
Annual revenue of Verax Biomedical is $498.01K as on Dec 31, 2023.
What does Verax Biomedical do?
Verax Biomedical was founded in 1999 and is based in Marlborough, United States, within the biomedical diagnostics sector. Pan-genera detection tests are developed by the company to identify bacterial contaminants in cells and tissues for transfusion and transplantation, utilizing conserved antigens from gram-positive and gram-negative bacteria. Operations include the Platelet PGD test, Red Blood PGD test, Cell Therapy PGD test, and 7-day platelet dating, as available in February 2016.
Who are the top competitors of Verax Biomedical?
Verax Biomedical's top competitors include Avails Medical, OpGen and NOWDiagnostics.
What products or services does Verax Biomedical offer?
Verax Biomedical offers Platelet PGD Test, Platelet PGD prime, Red Cell PGD Test, and Cell Therapy PGD Test.
Who are Verax Biomedical's investors?
Verax Biomedical has 6 investors. Key investors include BioVentures MedTech Funds, Teknoinvest, KB Partners, Clark Enterprises, and Sightline Partners.